Previous 10 | Next 10 |
home / stock / esalf / esalf news
2024-01-24 08:54:54 ET More on Biogen, Eisai Co., Ltd., etc. Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Eisai...
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan TOKYO, Jan 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulati...
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time TOKYO, Jan 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been listed in the 2024 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-bas...
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024 TOKYO, Jan 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and ...
2024-01-11 05:46:14 ET Biogen ( NASDAQ: BIIB ) and its Japanese partner Eisai ( OTCPK:ESALF ) have filed a marketing authorization application for their breakthrough Alzheimer's therapy, called Leqembi (lecanemab), in the EU. The application to the European Medicines Agency ...
Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU TOKYO, Jan 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the Scientific Advisory Group (SAG) will convene to discuss the marketing auth...
Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China TOKYO and CAMBRIDGE, Mass., Jan 10, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclona...
2024-01-09 05:30:25 ET Biogen ( NASDAQ: BIIB ) and its Japanese partner Eisai ( OTCPK:ESALF ) announced on Tuesday market approval for their breakthrough Alzheimer's therapy, called Leqembi, in China. Leqembi (lecanemab), a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor TOKYO, Dec 29, 2023 - (JCN Newswire) - Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta*1 (A&...
2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...